clear
small
proport
patient
develop
sever
diseas
risk
factor
old
age
presenc
comorbid
hypertens
diabet
obes
smoke
cardiovascular
lung
diseas
also
assum
peopl
immunocompromis
exampl
patient
multipl
sclerosi
ms
immunosuppress
diseasemodifi
therapi
dmt
also
increas
risk
sever
therefor
reassur
read
issu
case
report
patient
primari
progress
ms
previous
treat
ocrelizumab
bcell
deplet
monoclon
antibodi
develop
uncompl
novi
g
mikulska
briano
f
toscanini
f
tazza
f
uccelli
ingles
although
one
swallow
nt
make
summer
case
report
keep
onlin
account
mainli
social
media
patient
receiv
immunosuppress
ms
therapi
experienc
uncompl
instanc
patient
ms
sever
surprisingli
tend
older
comorbid
advanc
diseas
case
onlin
report
support
hypothesi
immunosuppress
least
moder
immunosuppress
associ
ms
dmt
may
protect
develop
sever
infect
unexpect
sever
pulmonari
complic
infect
consist
acut
respiratori
distress
syndrom
ard
appear
immunemedi
ramanathan
et
al
present
numer
exploratori
trial
sever
immunosuppress
therapi
underway
includ
fingolimod
modul
tocilizumab
antagonist
anakinra
receptor
antagonist
emapalumab
antiinterferongamma
monoclon
antibodi
current
test
treatment
associ
ard
recent
studi
uk
intens
care
nation
audit
research
centr
compar
patient
sever
patient
viral
pneumonia
admit
itu
uk
icnarc
proport
immunocompromis
patient
cohort
lower
viral
pneumonia
cohort
vs
p
figur
icnarc
websit
inform
like
bias
patient
deem
frail
andor
disabl
may
never
reach
itu
may
includ
disproportion
number
immunosuppress
patient
least
nonm
popul
impli
immunosuppress
therapi
may
associ
better
diseas
outcom
initi
antivir
respons
driven
mainli
tcell
particular
cytotox
tlymphocyt
natur
killer
cell
less
bcell
may
explain
patient
therapi
cope
rel
well
viral
infect
ocrelizumab
therapi
rel
minor
impact
tcell
count
associ
sever
viral
infect
mayer
et
al
ms
registr
trial
ocrelizumab
infect
slightli
frequent
ocrelizumab
compar
compar
arm
placebo
hauser
et
al
montalban
et
al
identifi
viral
infect
trial
mild
moder
sever
infect
like
bacteri
ie
pneumonia
urinari
tract
infect
cellul
howev
alway
rare
except
rule
exampl
singl
case
report
fulmin
hepat
associ
unusu
infect
patient
ocrelizumab
therapi
nicolini
et
al
novi
g
mikulska
briano
f
toscanini
f
tazza
f
uccelli
ingles
light
case
report
support
data
ms
commun
may
reconsid
advic
give
ms
dmt
pandem
alasdair
cole
ms
advisori
group
patient
highli
activ
ms
consequ
delay
treatment
delay
access
high
efficaci
therapi
need
consid
care
particularli
risk
individu
immunosuppress
patient
manag
selfisol
shield
withold
immunosuppress
therapi
activ
ms
may
unintent
increas
chanc
sever
realworld
data
collect
current
hope
provid
us
definit
answer
question
exist
emerg
data
indic
therapi
like
safe
initi
redos
pandem
last
five
year
receiv
research
grant
support
biogen
merck
novarti
roch
sanofigenzym
takeda
also
receiv
person
compens
particip
advisori
board
relat
clinic
trial
design
trial
steer
committe
data
safeti
monitor
committe
abbvi
actelion
atara
bio
biogen
canbex
celgen
genentech
medday
merck
novarti
roch
sanofigenzym
teva
